United States · Investor

Osage University Partners

Last cheque observed Aug 2026; 93 cheques on record.

Deploying nowNew fund $196M, Apr 2023VC firm

SeedSeries ASeries BGraduateEnvironnementMental Health

Deploying now
100%of best year3cheques in 12 months, 93 on record
Since the last cheque68days00hrs00min00sec
Median round$40MCheque size, as they say$5.0M – $20MRounds led0 of 93Sole investor3 roundsExits6 from the portfolioMostly inUnited States, 97%
Pitch Osage University Partners

Osage University Partners highlights

  1. 01

    3 cheques in the last 12 months

  2. 02

    Mostly Series A and Series B: 65% of its rounds

  3. 03

    Sole investor in 3 rounds, median $5.8M

  4. 04

    6 exits from the portfolio

What they do

Type
VC firm (from a list, unverified)
Cheque size
$5.0M – $20M as they say
Stages
SeedSeries ASeries BGrowthPre-IPO
Sectors
GraduateEnvironnementMental Health
Based in
Bala Cynwyd, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first93 appearances

  1. 2026

    3 rounds

  2. Aug
    QuintessentSeries A · US · Ventureburn$40MWith 12 others
  3. May
    Tessera LabsSeries A · TechStartups$60MWith 3 others
  4. Jan
    Nocion TherapeuticsSeries B · US · Lumira Ventures$23MWith 9 others
  5. 2025

    1 round

  6. Apr
    Atsena TherapeuticsSeries C · US · Hatteras Venture Partners$150MWith 9 others
  7. 2021

    2 rounds

  8. Sept
    Vanqua BioSeries B · US · Firms' own news pages$85MWith 8 others
  9. Mar
    Artizan Biosciences, Inc.Series A · US · Hatteras Venture Partners$11MWith 4 others
  10. 2019

    16 rounds

  11. Nov
    PMV PharmaSeries C · US · Prweb$62MWith 7 others
  12. Oct
    ArsenalBioSeries A · US · FinSMEs$85MWith 6 others
  13. Oct
    Cyteir TherapeuticsUS · FinSMEs$40MWith 5 others
  14. Aug
    Landos BiopharmaSeries B · US · FinSMEs$60MWith 3 others
  15. Aug
    Cleave TherapeuticsSeries C · US · Businesswire$12MWith 8 others
  16. Jul
    Menlo SecuritySeries D · US · FinSMEs$75MWith 7 others
  17. Jun
    EveractiveUS · Finance$30MWith 4 others
  18. Jun
    Artizan BiosciencesSeries A · US · Hatteras Venture Partners$12MWith 7 others
  19. Jun
    SiFiveSeries D · US · FinSMEs$65MWith 5 others
  20. May
    AlgorithmiaSeries B · US · FinSMEs$25MWith 5 others
  21. May
    LunaPBCUS · FinSMEs$4.6MWith 4 others
  22. Apr
    Sasuma PharmaceuticalsUS · Biospace$62MWith 9 others
  23. Apr
    Arrakis TherapeuticsSeries B · US · FinSMEs$75MWith 13 others
  24. Mar
    Hyalex OrthopaedicsSeries A · US · FinSMEs$33MWith 3 others
  25. Feb
    Vor BiopharmaSeries A · US · FinSMEs$42MWith 3 others
  26. Feb
    KenSciSeries B · US · FinSMEs$22MWith 4 others
  27. 2018

    9 rounds

  28. Aug
    StreetLight DataSeries C · US · FinSMEs$10MWith 2 others
  29. Jul
    AntivaSeries C · US · FinSMEs$15MWith 5 others
  30. Jun
    PrecisionSeries B · US · FinSMEs$110MWith 18 others
  31. Jun
    EmbodiedSeries A · US · FinSMEs$22MWith 3 others
  32. May
    MedisixSeries A · SG · DealStreetAsia$20MWith 2 others
  33. May
    EscientSeries A · US · FinSMEs$40MWith 2 others
  34. Apr
    SynthorxSeries C · US · FinSMEs$63MWith 4 others
  35. Feb
    CounterFlow AISeed · US · FinSMEs$2.7MSole investor
  36. Jan
    Ribon TherapeuticsSeries B · US · Marketwatch$65MWith 7 others
  37. 2017

    9 rounds

  38. Dec
    AptinyxSeries B · US · FinSMEs$70MWith 15 others
  39. Dec
    PionyrSeries B · US · FinSMEs$62MWith 5 others
  40. Dec
    Menlo SecuritySeries C · US · FinSMEs$40MWith 7 others
  41. Nov
    Quantum CircuitsSeries A · US · Boston$18MWith 3 others
  42. Jun
    AlgorithmiaSeries A · US · TechCrunch$11MWith 3 others
  43. Mar
    Antiva BiosciencesSeries C · US · FinSMEs$22MWith 4 others
  44. Mar
    Spero TherapeuticsSeries C · US · FinSMEs$52MWith 8 others
  45. Feb
    Arrakis TherapeuticsSeries A · US · FinSMEs$38MWith 4 others
  46. Feb
    PMV PharmaceuticalsSeries B · US · FinSMEs$74MWith 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration6 named

CDClaudia DunnousCFOiForm ADV
LPLouis P. BernemanMr. Berneman is also a Managing PartneriFiling they signed
MAMarc A. SingerManaging Member of the General PartneriFiling they signed
MSMatthew S. CohenManaging Member of the General PartneriFiling they signed
RSRobert s. AdelsonMr. Adelson is also a Managing PartneriFiling they signed
WSWilliam S. HarringtonMr. Harrington is also a managing partneriFiling they signed

We also hold 25 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$785Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
Legal name
OUP Management Co., LLC
SEC number
CRD 312857

What they claim to have backed

From their own portfolio page (on their website)

0 of 3 we have independently watched raise

Investor PortalMemberhere

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

Exits from the portfolio

Companies it backed that were later bought or listed6 in all

Body LabsBought by Amazon$60MOct 2017
ReceptosBought by Celgene$7.3BJul 2015
SolarBridge TechnologiesBought by SunPower CorporationUndisclosedNov 2014
Aerie PharmaceuticalsListedUndisclosedOct 2013
Avid RadiopharmaceuticalsBought by Eli Lilly$800MNov 2010

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Osage University Partners. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Osage University Partners put money into.

Quick answers about Osage University Partners

What does Osage University Partners invest in?

Osage University Partners invests most often at Series A and Series B (65% of the rounds on record), in sectors such as Graduate, Environnement and Mental Health.

How active is Osage University Partners?

93 investments on record, 3 of them in the last 12 months. The most recent was in Aug 2026.

What has Osage University Partners invested in recently?

Its most recent investments on record: Quintessent (Series A, Aug 2026), Tessera Labs (Series A, May 2026) and Nocion Therapeutics (Series B, Jan 2026).

How big are Osage University Partners's cheques?

The median round it joins is $40M. It says it writes cheques of $5.0M to $20M.

Does Osage University Partners lead rounds?

Rarely, if at all: none of its 93 investments on record names it as the lead.

Where does Osage University Partners invest?

Most of the companies it backs are in the United States (97%).

Is Osage University Partners investing now?

Yes: it is actively investing, with 3 investments in the last 12 months.

Who does Osage University Partners invest alongside?

Most often OrbiMed (11 rounds together), New Enterprise Associates (8 rounds together) and Canaan (6 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it